Risk stratification of sentinel node–positive melanoma patients defines surgical management and adjuvant therapy treatment considerations
D. Verver(Erasmus MC Cancer Institute), Dirk J. Grünhagen(Erasmus MC), Astrid A.M. van der Veldt(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Barbara L. van Leeuwen(University Medical Center Groningen), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Alexander M.M. Eggermont(University Medical Center Utrecht), Ulrich Keilholz(German Cancer Research Center), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Alexander C. J. van Akkooi(The University of Sydney), Caroline Robert(Institut Gustave Roussy), Cornelis Verhoef(Erasmus MC Cancer Institute), Barry Powell(St George's Hospital), David van Klaveren(Erasmus MC)
Cited by 68
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k